Formulary Search - PAD Formulary

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Hyperprolactinaemia (Cabergoline - Hyperprolactinaemia)

Records returned : 2 (on 25 Nov 2024 at 00:53:41). Return to search results for ' Hyperprolactinaemia '.

Drug

Indication

Status

Trust Alignment

Links

Restrictions/Comments

04.09.01

06.07.01

Cabergoline

Hyperprolactinaemia

Blue

Formulations :

Tablets

ASPH

RSFT

SASH

SABP

Primary Care

BNF SPC

Important

Preferred

Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/

06.07.01

Bromocriptine

Hyperprolactinaemia

Blue

Formulations :

Tablets

ASPH

RSFT

SASH

SABP

Primary Care

BNF SPC

Important

Cabergoline should be considered 1st-line. Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility pf secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

ICB

Treatment commissioned by the ICB

BlueTeq

BlueTeq form to be completed

NICE

Traffic Light Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Black

Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.

Amber Star

Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)

See Below

Please add a description.

N/A

Please add a description.

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green - Black

Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.

See narrative

See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)

Do not initiate in new patients

These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)